Last reviewed · How we verify
NCT07029230
Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
trial in Congenital Heart Surgery in 225 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Martin Schweiger |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 225 |
| Start date | 10 September 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 January 2029 |
| Sites | 1 location across Switzerland |
Conditions studied
- Congenital Heart Surgery — all drugs for Congenital Heart Surgery →
- Congenital Heart Disease in Children — all drugs for Congenital Heart Disease in Children →
- Fontan Physiology — all drugs for Fontan Physiology →
Sponsor
Martin Schweiger
Who can join
Under 18, any sex, with Congenital Heart Surgery or Congenital Heart Disease in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07029230
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07029230 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Martin Schweiger
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07029230.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing